Therapeutic targets in melanoma: map kinase pathway.

Article Details

Citation

Copy to clipboard

Haluska FG, Ibrahim N

Therapeutic targets in melanoma: map kinase pathway.

Curr Oncol Rep. 2006 Sep;8(5):400-5.

PubMed ID

16901402 [ View in PubMed

]

Abstract

Recent progress in our understanding of the genetic alterations that occur in the pathogenesis of melanoma provides exciting opportunities for therapy. The most important signaling pathways in melanoma lie downstream of NRAS: the RAS-BRAF-MAPK pathway. A great deal of attention has been focused on the high mutation rate in the BRAF oncogene, which approaches 60%, because BRAF itself is an appealing drug substrate and because of the central contribution of BRAF function to melanoma development that the mutation rate signifies. Agents that specifically target BRAF, such as sorafenib, as well as new molecules that function both upstream and downstream of BRAF, are being actively investigated.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Sorafenib	Serine/threonine-protein kinase B-raf	Protein	Humans	Yes	Inhibitor	Details